CN113244372B - Composition for enhancing immunity and preparation process and application thereof - Google Patents
Composition for enhancing immunity and preparation process and application thereof Download PDFInfo
- Publication number
- CN113244372B CN113244372B CN202110435276.2A CN202110435276A CN113244372B CN 113244372 B CN113244372 B CN 113244372B CN 202110435276 A CN202110435276 A CN 202110435276A CN 113244372 B CN113244372 B CN 113244372B
- Authority
- CN
- China
- Prior art keywords
- solvent
- parts
- mixing
- composition
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of health products, in particular to a composition for enhancing immunity, a preparation process and application thereof, wherein the composition comprises the following components: 37. the invention has the advantages of good immunity enhancing effect, simple preparation process and no side effect.
Description
Technical Field
The invention relates to the technical field of health products, in particular to a composition for enhancing immunity, a preparation process and application thereof.
Background
Immunity is the body's own defense mechanism, which is the body's ability to recognize and eliminate any foreign body (viruses, bacteria, etc.) that invade from outside, to treat aging, injury, death, degenerated own cells, and to recognize and treat mutant cells and virus-infected cells in the body, and is the body's physiological response to recognize and exclude "abnormal".
A body with low immunity is susceptible to infection or cancer; the immunity is very common and can also produce harmful effects to the body, such as eliciting allergic reactions, autoimmune diseases, etc. The immune system cannot normally play a protective role due to various reasons, and in this case, infections such as bacteria, viruses and fungi are extremely liable to occur, so that the most direct manifestation of low immunity is easy to be ill. Because of frequent illness and aggravated consumption of organisms, the health and weakness, malnutrition, listlessness, fatigue and weakness, appetite reduction, sleep disturbance and other manifestations are common, and the medical injection and medication are convenient for family use. Each illness takes a long time to recover and often recurs. Long-term development of physical and mental retardation and susceptibility to serious diseases.
Modern medical science has found that immunity is a factor closely related to aging, and hypoimmunity is one of the most important causes of aging. Some special cells of the immune system of the organism can generally phagocytize and destroy bacteria, viruses, cells which invade the body and die after aging, mutated cells and substances which cause allergic reactions, thereby keeping the environment in the body stable and keeping the body healthy. However, the immune function of the body begins to decline around the age of 30 years, and the change is silently, slowly and continuously performed. In addition, fast paced lifestyles, excessive exertion, can also lead to reduced autoimmunity.
Besides regulating daily life habit, the immunity can be improved, trace elements, vitamins and the like can be supplemented for assistance, or some oral medicines can be taken. However, the currently used medicines are often poor in effect, complex in components and high in cost, and a plurality of side effects are often caused after the medicines are taken.
The Chinese patent application CN110893230A provides a traditional Chinese medicine composition for improving immunity, which has the functions of improving immunity, resisting infection and preventing and resisting cancer, and is prepared from the following components: 20-40 parts of lentinus edodes, 20-40 parts of sea cucumber dry powder, 20-40 parts of cordyceps militaris, 20-40 parts of Chinese yam, 10-20 parts of astragalus membranaceus, 2-5 parts of cynomorium songaricum, 2-5 parts of epimedium, 2-5 parts of mulberry, 2-5 parts of gardenia root, 1-2 parts of asparagus fern, 1-2 parts of melastoma dodecandrum, 1-2 parts of mussel flower, 1-2 parts of dried ginger, 1-2 parts of Japanese ardisia herb and 1-2 parts of fennel root. The traditional Chinese medicine raw materials are dried according to the formula proportion, crushed into 100-200 meshes of fine powder, and uniformly mixed to prepare the finished product. The traditional Chinese medicine composition provided by the invention has the advantages of safety, effectiveness, high cost performance and the like, and can improve the immunity.
Chinese patent application CN109908318A discloses a pharmaceutical composition for improving immunity and a preparation method thereof, which comprises the following raw materials: astragalus root, walnut kernel, medlar, chinese yam, gorgon fruit, prepared rhizome of rehmannia, liquorice, brown sugar, tuckahoe, cinnamon, white paeony root, ginger leaf, dogwood, reed rhizome, pine needle, raw costustoot, dandelion, cassia seed, red-rooted salvia root, cuttlebone, cherokee rose fruit, bupleurum, eclipta, bamboo leaf, medicated leaven and pine needle. Also discloses a preparation method of the pharmaceutical composition for improving immunity. The invention scientifically combines a plurality of raw materials, has the advantages of synergistic effect of the functions of the raw materials, simple production process, qi tonifying, exterior strengthening, mild effect, capability of improving immunity, relieving sub-health state, improving antiviral capability and improving physical quality.
Chinese patent application CN111920902A discloses a traditional Chinese medicine composition for improving immunity and a preparation method thereof, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight: ginseng, ginseng leaf, ginseng root, leek seed, cuscuta seed, angelica, dangshen, nutgrass galingale rhizome, accumulated shell, accumulated fruit, dried rehmannia root, bupleurum, kudzuvine root, lily, dwarf lilyturf tuber, yam, tuber fleeceflower root, dark plum, basin-covered seed, fresh purslane, red sage root, glossy privet seed, eclipta, motherwort, common curculigo rhizome, black soybean, rhubarb, pilose antler, sea horse, desertliving cistanche, acanthopanax root, pseudoginseng, shizandra berry and epimedium. The Chinese medicinal composition can improve immunity, supplement hormone deficiency of female, promote female function balance, relieve fatigue, delay aging, and promote recovery of sub-health female.
However, the pharmaceutical composition consists of various traditional Chinese medicine components, has complex treatment mechanism, more uncontrollable factors and unstable treatment effect.
Therefore, it is necessary to develop a composition for enhancing immunity, and a preparation process and application thereof, which can solve the above-mentioned problems.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a composition with good immunity enhancing effect, simple preparation process and no side effect, and a preparation process and application thereof.
The invention is realized by the following technical scheme:
a composition comprising the following components: 37. folic acid, fructus Lycii, ganoderma extract, annona squamosa Linn and alpha-mannatide.
Preferably, the composition comprises the following components in parts by weight: 12-18 parts of pseudo-ginseng, 0.008-0.015 part of folic acid, 5-12 parts of medlar, 6-15 parts of lucid ganoderma extract, 6-11 parts of sweetsop and 5-9 parts of alpha-mannatide.
The invention also relates to a preparation process of the composition, which comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing, extracting with solvent A, and filtering to obtain residue 1 and filtrate 1;
(2) Pulverizing Notoginseng radix, mixing with the residue 1, extracting with solvent B, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Preferably, in the step (1), 85-95wt% of ethanol is added for extraction, and then 50-70wt% of ethanol is added for extraction.
Preferably, in the step (1), the medlar and the sweetsop are mixed and then crushed into 10-20 meshes.
Preferably, solvent A in step (1) is 50-95wt% ethanol.
Preferably, the solvent A is added in step (1) for 1-2 times.
Preferably, the extraction temperature of step (1) is 40-60 ℃.
More preferably, step (1) comprises the steps of: mixing fructus Lycii and fructus Annonae, pulverizing to 10-20 mesh, adding 3-6 times of 85-95wt% ethanol, extracting at 40-60deg.C for 60-100min, filtering, adding 3-6 times of 50-70wt% ethanol, extracting at 40-60deg.C for 40-60min, and filtering to obtain residue 1 and filtrate 1.
Preferably, in the step (2), the solvent B is a mixed solvent of dichloromethane-acetone-absolute ethyl alcohol, and the volume ratio of the solvent B to the solvent B is 1-3:1:2-4.
Preferably, in the step (2), the notoginseng is crushed to 10-20 meshes.
Preferably, the extraction temperature in step (2) is 30-50 ℃.
Preferably, the extraction time in step (2) is 1-2h.
More preferably, step (2) comprises the steps of: pulverizing Notoginseng radix to 10-20 mesh, mixing with the residue 1, adding 4-8 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the solvent B to the solvent is 1-3:1:2-4), extracting at 30-50deg.C for 1-2 hr, and filtering to obtain filtrate 2.
Preferably, the filtrates 1 and 2 in step (3) are combined and concentrated to a relative density of 1.2-1.3 at 60 ℃.
More preferably, the process for preparing the composition comprises the steps of:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 10-20 mesh, adding 3-6 times of 85-95wt% ethanol, extracting at 40-60deg.C for 60-100min, filtering, adding 3-6 times of 50-70wt% ethanol, extracting at 40-60deg.C for 40-60min, and filtering to obtain residue 1 and filtrate 1;
(2) Pulverizing Notoginseng radix to 10-20 mesh, mixing with the residue 1, adding 4-8 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the solvent B to the solvent is 1-3:1:2-4), extracting at 30-50deg.C for 1-2 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.2-1.3 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
The invention also relates to a preparation comprising the composition or the composition prepared by the preparation process.
The invention also relates to the application of the composition or the composition prepared by the preparation process or the preparation in preparing the health care product for enhancing immunity.
The beneficial effects of the invention are as follows:
the invention obviously improves the effect of enhancing the immunity and has no side effect by optimizing the composition of the composition and the dosage proportion of each component, and the synergistic effect of each component, especially the synergistic effect among pseudo-ginseng, medlar and sweetsop and the synergistic effect between folic acid and alpha-mannatide.
According to the invention, the extraction sequence of the raw materials is optimized, the medlar and the sweetsop are mixed for extraction, and the filter residue obtained by extraction is mixed with the pseudo-ginseng for extraction.
According to the invention, the types of solvents adopted in the extraction process are optimized, ethanol with different concentrations is sequentially adopted in the extraction process of the medlar and the sweetsop, the composition of the notoginseng and the solvent B in the extraction process of the filter residue 1 is optimized, the synergistic effect of the active ingredients in the prepared composition is more obvious, the effect of improving the immunity is further enhanced, and no side effect is generated.
Detailed Description
The invention will be further described with reference to specific embodiments, and advantages and features of the invention will become apparent from the description. These examples are merely exemplary and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
The ganoderma lucidum extracts of the examples and comparative examples of the present invention were purchased from the company of the biological technology of cisapride, with a specification content of 10:1.
Example 1
The composition comprises the following components in parts by weight: 12 parts of pseudo-ginseng, 0.008 part of folic acid, 5 parts of medlar, 6 parts of lucid ganoderma extract, 6 parts of sweetsop and 5 parts of alpha-mannatide.
The preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 10 mesh, extracting with 3 times of 85wt% ethanol at 40deg.C for 60min, filtering, extracting the residue with 3 times of 50wt% ethanol at 40deg.C for 40min, filtering to obtain residue 1, and mixing the two filtrates to obtain filtrate 1;
(2) Pulverizing Notoginseng radix to 10 mesh, mixing with the residue 1, adding 4 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the three is 1:1:2), extracting at 30deg.C for 1 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.2 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Example 2
The composition comprises the following components in parts by weight: 18 parts of pseudo-ginseng, 0.015 part of folic acid, 12 parts of medlar, 15 parts of lucid ganoderma extract, 11 parts of sweetsop and 9 parts of alpha-mannatide.
The preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 20 mesh, adding 6 times of 95wt% ethanol, extracting at 60deg.C for 100min, filtering, adding 6 times of 70wt% ethanol, extracting at 60deg.C for 60min, filtering to obtain residue 1, and mixing the two filtrates to obtain filtrate 1;
(2) Pulverizing Notoginseng radix to 20 mesh, mixing with the residue 1, adding 8 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the three is 3:1:4), extracting at 50deg.C for 2 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.3 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Example 3
The composition comprises the following components in parts by weight: 15 parts of pseudo-ginseng, 0.01 part of folic acid, 8 parts of medlar, 10 parts of lucid ganoderma extract, 8 parts of sweetsop and 7 parts of alpha-mannatide.
The preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 20 mesh, extracting with 5 times of 90wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 60wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1, and mixing the two filtrates to obtain filtrate 1;
(2) Pulverizing Notoginseng radix to 20 mesh, mixing with the residue 1, adding 6 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the three is 2:1:3), extracting at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 1
The difference from example 3 is that no pseudo-ginseng is added, the dosage of the medlar and the sweetsop is changed, and the other conditions are the same, and the concrete steps are as follows:
the composition comprises the following components in parts by weight: 0.01 part of folic acid, 15.5 parts of medlar, 10 parts of lucid ganoderma extract, 15.5 parts of sweetsop and 7 parts of alpha-mannatide.
The preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 20 mesh, extracting with 5 times of 90wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 60wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1, and mixing the two filtrates to obtain filtrate 1;
(2) Extracting the filter residue 1 with 6 times of solvent B (the solvent B is mixed solvent of dichloromethane-acetone-absolute ethanol, and the volume ratio of the solvent B to the solvent B is 2:1:3) at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 2
The difference from example 3 is that the dosage of notoginseng is changed without adding medlar and sweetsop, and the other conditions are the same, and the concrete steps are as follows:
the composition comprises the following components in parts by weight: 31 parts of pseudo-ginseng, 0.01 part of folic acid, 10 parts of ganoderma lucidum extract and 7 parts of alpha-mannatide.
The preparation process of the composition comprises the following steps:
(1) Pulverizing Notoginseng radix to 20 mesh, adding 6 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, and the volume ratio of the solvent B to the solvent is 2:1:3), extracting at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(2) Concentrating the filtrate 2 to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 3
The only difference from example 3 is the preparation process of the composition, the remaining conditions are the same, and the specific conditions are as follows:
the preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii, fructus Annonae and Notoginseng radix, pulverizing to 20 mesh, extracting with 5 times of 90wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 60wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1, and mixing the filtrates to obtain filtrate 1;
(2) Extracting the filter residue 1 with 6 times of solvent B (the solvent B is mixed solvent of dichloromethane-acetone-absolute ethanol, and the volume ratio of the solvent B to the solvent B is 2:1:3) at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 4
The only difference from example 3 is the preparation process of the composition, the remaining conditions are the same, and the specific conditions are as follows:
the preparation process of the composition comprises the following steps:
(1) Pulverizing fructus Lycii to 20 mesh, extracting with 5 times of 90wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 60wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1-1, and mixing the two filtrates to obtain filtrate 1-1;
(2) Pulverizing Annona squamosa Linn to 20 mesh, extracting with 5 times of 90wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 60wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1-2, and mixing the two filtrates to obtain filtrate 1-2;
(3) Pulverizing Notoginseng radix to 20 mesh, mixing with residue 1-1 and residue 1-2, adding 6 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the three is 2:1:3), extracting at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(4) Mixing filtrate 1-1, filtrate 1-2 and filtrate 2, concentrating to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 5
The difference from example 3 is only that in step (1) 60wt% ethanol is used first, then 90wt% ethanol is used for extraction, and the other conditions are the same, specifically as follows:
the preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 20 mesh, extracting with 5 times of 60wt% ethanol at 50deg.C for 80min, filtering, extracting the residue with 5 times of 90wt% ethanol at 50deg.C for 50min, filtering to obtain residue 1, and mixing the two filtrates to obtain filtrate 1;
(2) Pulverizing Notoginseng radix to 20 mesh, mixing with the residue 1, adding 6 times of solvent B (solvent B is mixed solvent of dichloromethane-acetone-anhydrous ethanol, the volume ratio of the three is 2:1:3), extracting at 40deg.C for 1.5 hr, and filtering to obtain filtrate 2;
(3) Mixing the filtrates 1 and 2, concentrating to relative density of 1.25 at 60deg.C, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying.
Comparative example 6
The difference from example 3 is that the composition of the solvent B in the step (2) is different, and the solvent B is a mixed solvent of dichloromethane-acetone-absolute ethyl alcohol, and the volume ratio of the solvent B to the solvent B is 2:3:1.
Test example 1
Enhancing immune function test
1. Sample to be tested: the compositions of examples 1-3 and comparative examples 1-6.
2. Experimental animals and environment: SPF KM female mice, body weight 18-22g; laboratory animal temperature: 22-25 ℃, relative humidity: 55-70%.
3. The experimental method comprises the following steps: the mice were randomly divided into 10 groups of 5 mice each, which were respectively an experimental group (total 3 groups, composition of examples 1 to 3 by gavage according to 0.5 g/kg.bw), a control group (total 6 groups, composition of comparative examples 1 to 6 by gavage according to 0.5 g/kg.bw), and a negative control group (distilled water of equal volume by gavage), and the mice were gavaged for 30 days.
3.1 ConA-induced mouse spleen lymphocyte transformation experiments
After each group of test mice was continuously perfused with the prescribed dose for 30d, the mice were sacrificed by cervical dislocation, and the spleens were aseptically removed to prepare single cell suspensions (cell concentration 1×10) 7 and/mL). The spleen cell suspensions of mice were added to 24-well plates, each treatment using two duplicate wells, 1mL per well, 50. Mu.L ConA was added to one well and 50. Mu.L double distilled water was added to the other well as a control, and the plates were then placed in 5% CO 2 Culturing in a carbon dioxide incubator at 37 ℃ for 48 hours. 4h before the end of the incubation, MTT (5 mg/mL) 50 was addedAnd (3) adding 1mL of DMSO into each well after the culture is finished, blowing and uniformly mixing to completely dissolve the purple crystals, subpackaging the mixture into 96-well culture plates, subpackaging 3 multiple wells into each well, and measuring the OD value at 570nm wavelength by using an enzyme-labeled instrument. The optical density value of the ConA-added wells minus the optical density value of the ConA-not-added wells represents the proliferation capacity of lymphocytes. Proliferation capacity of lymphocytes = ConA well OD value-control well OD value. The results are shown in Table 1.
TABLE 1
| Group of | Proliferation capacity of lymphocytes |
| Negative control group | 0.059±0.009 a |
| Example 1 | 0.138±0.021 b |
| Example 2 | 0.140±0.015 b |
| Example 3 | 0.142±0.043 b |
| Comparative example 1 | 0.122±0.025 c |
| Comparative example 2 | 0.119±0.027 c |
| Comparative example 3 | 0.125±0.032 c |
| Comparative example 4 | 0.128±0.011 c |
| Comparative example 5 | 0.133±0.039 c |
| Comparative example 6 | 0.130±0.035 c |
a. The different letters of b and c represent significant differences among the negative control group, the experimental group and the control group.
3.2 Dinitrofluorobenzene (DNFB) induced delayed type allergy (DTH) test
After the stomach of each group of test mice is continuously irrigated for 30d according to the set dose, the abdomen of the mice is dehaired, 50 mu L of 1% DNFB acetone sesame oil solution is smeared for sensitization, 5d after sensitization, 10 mu L of 1% DNFB acetone sesame oil solution is smeared on the right ear of the mice uniformly, the same amount of acetone sesame oil solution is smeared on the left ear as a control, the mice are sacrificed 24h after the challenge, the left ear shell and the right ear shell are cut off, the ears with the diameter of 8mm are weighed at the same position, and the difference between the weights of the left ear piece and the right ear piece is taken as the swelling degree. The results are shown in Table 2.
TABLE 2
d. e, f, the negative control group, the experimental group and the control group have significant differences among different letters.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (5)
1. The composition for enhancing immunity is characterized by comprising the following components in parts by weight: 12-18 parts of pseudo-ginseng, 0.008-0.015 part of folic acid, 5-12 parts of medlar, 6-15 parts of lucid ganoderma extract, 6-11 parts of sweetsop and 5-9 parts of alpha-mannatide;
the preparation process of the composition comprises the following steps:
(1) Mixing fructus Lycii and fructus Annonae, pulverizing to 10-20 mesh, adding 3-6 times of 85-95wt% ethanol, extracting at 40-60deg.C for 60-100min, filtering, adding 3-6 times of 50-70wt% ethanol, extracting at 40-60deg.C for 40-60min, and filtering to obtain residue 1 and filtrate 1;
(2) Pulverizing Notoginseng radix, mixing with the residue 1, extracting with solvent B, and filtering to obtain filtrate 2; (3) Mixing the filtrates 1 and 2, concentrating, mixing with Ganoderma extract, folic acid and alpha-mannatide, and drying to obtain the final product;
in the step (2), the solvent B is a mixed solvent of dichloromethane-acetone-absolute ethyl alcohol, and the volume ratio of the solvent B to the solvent B is 1-3:1:2-4.
2. The composition of claim 1, wherein step (2) comprises the steps of: pulverizing Notoginseng radix to 10-20 mesh, mixing with the residue 1, adding 4-8 times of solvent B, extracting at 30-50deg.C for 1-2 hr, and filtering to obtain filtrate 2.
3. The composition of claim 1, wherein the filtrates 1 and 2 in step (3) are combined and concentrated to a relative density of 1.2-1.3 at 60 ℃.
4. An immunity enhancing formulation comprising the composition of any one of claims 1-3.
5. Use of a composition according to any one of claims 1 to 3 or a formulation according to claim 4 for the preparation of a health product for enhancing immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110435276.2A CN113244372B (en) | 2021-04-22 | 2021-04-22 | Composition for enhancing immunity and preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110435276.2A CN113244372B (en) | 2021-04-22 | 2021-04-22 | Composition for enhancing immunity and preparation process and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113244372A CN113244372A (en) | 2021-08-13 |
| CN113244372B true CN113244372B (en) | 2023-04-28 |
Family
ID=77221249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110435276.2A Active CN113244372B (en) | 2021-04-22 | 2021-04-22 | Composition for enhancing immunity and preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113244372B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885301A (en) * | 2012-09-19 | 2013-01-23 | 北京同仁堂健康药业股份有限公司 | Composition for enhancing immunity and preparation method thereof |
| CN106215118A (en) * | 2016-08-29 | 2016-12-14 | 广西康宝海美三高生态茶有限公司 | Antineoplastic health preparation and preparation method thereof |
| JP2017101006A (en) * | 2015-12-04 | 2017-06-08 | 一丸ファルコス株式会社 | Glycerol production enhancer derived from staphylococcus-epidermidis, antimicrobial peptide production enhancer derived from skin epidermal keratinocyte, and their application to external preparations for skin protection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127304A (en) * | 2013-03-12 | 2013-06-05 | 丁国成 | Composition for enhancing immunity and preparation process of composition |
| CN106214847A (en) * | 2016-08-31 | 2016-12-14 | 江西利人生物科技有限公司 | A kind of can the oral liquid and preparation method thereof of enhancing immunity |
| CN107746785A (en) * | 2017-12-14 | 2018-03-02 | 荣成市飞创科技有限公司 | A kind of preparation method for improving immunity health liquor |
| CN108497478A (en) * | 2018-02-24 | 2018-09-07 | 成都中医药大学 | A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application |
| CN109350705B (en) * | 2018-12-24 | 2021-11-30 | 建昌帮药业有限公司 | Composition with effects of enriching blood, beautifying and enhancing immunity and application |
| CN111840466A (en) * | 2020-07-14 | 2020-10-30 | 重庆师范大学 | Medical health-care product for enhancing immunity and assisting in treating tumors and preparation method thereof |
| CN112076266A (en) * | 2020-09-30 | 2020-12-15 | 望谟县益民现代农业科技有限公司 | Ganoderma lucidum spore powder buccal tablet and preparation method thereof |
-
2021
- 2021-04-22 CN CN202110435276.2A patent/CN113244372B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885301A (en) * | 2012-09-19 | 2013-01-23 | 北京同仁堂健康药业股份有限公司 | Composition for enhancing immunity and preparation method thereof |
| JP2017101006A (en) * | 2015-12-04 | 2017-06-08 | 一丸ファルコス株式会社 | Glycerol production enhancer derived from staphylococcus-epidermidis, antimicrobial peptide production enhancer derived from skin epidermal keratinocyte, and their application to external preparations for skin protection |
| CN106215118A (en) * | 2016-08-29 | 2016-12-14 | 广西康宝海美三高生态茶有限公司 | Antineoplastic health preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113244372A (en) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101332256B (en) | Traditional Chinese medicine composition for infectious bursal disease and preparation method thereof | |
| CN112535239A (en) | Compound Chinese herbal medicine feed additive for daily health care and growth promotion of livestock and preparation and application thereof | |
| CN113244372B (en) | Composition for enhancing immunity and preparation process and application thereof | |
| CN104621310A (en) | Health tea and application thereof | |
| CN111214637A (en) | Traditional Chinese medicine composition and preparation method and medicinal application thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN109331107B (en) | Traditional Chinese medicine composition and oral liquid for preventing and treating pet viral myocarditis and preparation method thereof | |
| CN105362645A (en) | Preparation method of pharmaceutical composition for treating oral inflammations | |
| CN111346172B (en) | Pharmaceutical composition for improving immunity | |
| CN105434895A (en) | Gastrodia elata rhodiola rosea cream and preparation method thereof | |
| CN105124167B (en) | A kind of resisting stress Chinese herbal feed additive and preparation method and application | |
| CN108721520A (en) | It is a kind of to be used to improve oral solution of immunity and preparation method thereof | |
| CN107126508A (en) | A kind of pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN117942376A (en) | Application of composition in preparation of immunity-improving medicine | |
| CN105639636A (en) | Health care food with liver protection and blood sugar reduction functions and making method thereof | |
| CN107773621B (en) | Health food composition for enhancing immunity and preparation method thereof | |
| CN105395831A (en) | A medicine composition for treating oral inflammation | |
| CN118021921A (en) | Traditional Chinese medicine composition for preventing and treating animal anemia as well as preparation method and application thereof | |
| CN112138090A (en) | Traditional Chinese medicine composition capable of regulating human immunity and preparation method thereof | |
| CN105920526B (en) | Millettia speciosa champ composition for regulating immunity and preparation method and application thereof | |
| CN105311419A (en) | Traditional Chinese medicine composition for treating oral inflammations and preparation method thereof | |
| CN113577189A (en) | Traditional Chinese medicine composition for poultry and preparation method and application thereof | |
| CN111481631A (en) | Traditional Chinese medicine composition for enhancing physique and preparation method thereof | |
| CN114869966A (en) | A Chinese medicinal composition with vital essence promoting effect, and its preparation method | |
| CN116077578A (en) | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |